Ten months af­ter dev­as­tat­ing fail­ure, Roche says it sees path for­ward for Hunt­ing­ton’s drug

If you had to pick 2021’s biggest drug de­vel­op­ment dis­ap­point­ment, it’d be hard to over­look the Roche-Io­n­is Hunt­ing­ton’s dis­ease tri­al.

The Phase III study rep­re­sent­ed the com­mu­ni­ty’s first ma­jor hope of hav­ing a treat­ment for the un­der­ly­ing cause of a dev­as­tat­ing dis­ease that steals most pa­tients’ cog­ni­tion in mid-life. Then, in March, Roche had to cut the tri­al short be­cause the drug seemed to some­how be mak­ing pa­tients worse. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER